Literature DB >> 16131446

Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.

P Cejas1, M A García-Cabezas, E Casado, J Barriuso, J A Fresno, E Díaz, C Belda-Iniesta, J Castro, E Espinosa, P Zamora, J Feliu, A Redondo, D A Hardisson, M González-Barón.   

Abstract

INTRODUCTION: A number of findings suggest that cyclooxygenase-2 (COX-2) is overexpressed in breast tumours. However, there is a lack of consensus in the literature regarding the pattern of expression of this protein in invasive breast ductal carcinoma and in the adjacent non-tumour ductal epithelium. This study compares the expression of COX-2 mRNA and protein in breast ductal carcinoma relative to non-tumour breast tissue.
MATERIAL AND METHODS: We analysed the expression of COX-2 mRNA by quantitative PCR, and COX-2 protein by immunohistochemistry in invasive ductal carcinoma as well as in non-tumour adjacent ductal epithelium from 34 breast biopsies diagnosed as being invasive ductal carcinoma. As control, we analysed expression of COX-2 protein by immunohistochemistry in surgically-resected benign breast lesions.
RESULTS: Our results show that COX-2 mRNA and protein are overexpressed in non-tumour ductal epithelium compared with invasive ductal carcinoma. However, the pattern of the protein expression is different in tumour and non-tumour tissue: COX-2 protein is expressed predominantly in the membrane of the non-tumour ductal epithelium (including in benign breast lesions) while, in invasive ductal carcinoma cells, it is localised in the cytoplasm.
CONCLUSIONS: The non-tumour ductal epithelium adjacent to invasive ductal carcinoma shows a higher COX-2 expression than does the invasive ductal carcinoma. However, the different localisation of the immunohistochemically-detected protein suggests a possible post-translational regulation of the protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131446     DOI: 10.1007/BF02710169

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  15 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Authors:  Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

3.  COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

Authors:  R A Soslow; A J Dannenberg; D Rush; B M Woerner; K N Khan; J Masferrer; A T Koki
Journal:  Cancer       Date:  2000-12-15       Impact factor: 6.860

4.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

5.  Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.

Authors:  Pia Wülfing; Raihanatou Diallo; Christine Müller; Christian Wülfing; Christopher Poremba; Achim Heinecke; Achim Rody; Robert R Greb; Werner Böcker; Ludwig Kiesel
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

6.  p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.

Authors:  J J Sirvent; M T Salvadó; M Santafé; S Martínez; J Brunet; T Alvaro; J Palacios
Journal:  Histol Histopathol       Date:  1995-07       Impact factor: 2.303

7.  Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.

Authors:  Veronica Shim; Mona L Gauthier; Daniel Sudilovsky; Kristin Mantei; Karen L Chew; Dan H Moore; Imok Cha; Thea D Tlsty; Laura J Esserman
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Expression of cyclooxygenase-2 in malignant and benign breast tumors.

Authors:  Osamu Watanabe; Tadao Shimizu; Hiroshi Imamura; Jun Kinoshita; Yoshihito Utada; Toshihiro Okabe; Kiyomi Kimura; Akira Hirano; Kazuhiko Yoshimatsu; Motohiko Aiba; Kenji Ogawa
Journal:  Anticancer Res       Date:  2003 Jul-Aug       Impact factor: 2.480

Review 9.  Epidemiology of non-steroidal anti-inflammatory drugs and cancer.

Authors:  John A Baron
Journal:  Prog Exp Tumor Res       Date:  2003

10.  Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators.

Authors:  M P Schrey; K V Patel
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more
  1 in total

1.  Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue.

Authors:  Mohammad A Mohammad; Ahmed A Zeeneldin; Zakaria Y Abd Elmageed; Ebtsam H Khalil; Said M E Mahdy; Hayat M Sharada; Sabry K Sharawy; Abdel-Hady A Abdel-Wahab
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.